Morocco Strategic Minerals Corporation announced on Thursday the results of its July 2025 channel sampling and selected ...

Accepting the bioequivalence (BE) study report, the Subject Expert Committee (SEC) functional under the Central Drugs ...

Viking Therapeutics' stock drops 40% despite strong Phase 2 weight-loss drug results. See here to know why I remain ultra ...

About ASCO Contact Us Licensing ASCO Overview Press Center Careers at ASCO Mobile Apps Conference Center Rental Association for Clinical Oncology ...

People with type 2 diabetes treated with GLP-1 receptor agonists may face a slightly higher risk for eye complications ...

Viking Therapeutics has reported phase 2 data on its oral obesity drug candidate, linking the peptide to weight loss of up to 12.2% after 13 weeks. But, with 38% of patients discontinuing treatment at ...

Structure Therapeutics has dropped over 55% as its GLP-1 pill targets obesity, yet analysts remain bullish with high price ...

The Phase II VENTURE-Oral Dosing study of VK2735 met primary and secondary endpoints, with once-daily treatment leading to progressive weight reductions, high responder rates, and encouraging safety ...

A new bat organoid platform has been used to study zoonotic viruses like SARS-CoV-2 and flu, revealing more about viral ...

Longer-term data show that donanemab’s cognitive benefits continue to grow over time, and earlier initiation reduces the risk for progression, with no new safety signals.

Structure Therapeutics Inc. (NASDAQ:GPCR) is one of the best small cap stocks with biggest upside potential. On August 7, ...

Viking shares fell on Phase 2 obesity pill data as tolerability issues surfaced, but William Blair says the stock's sell-off ...